Purpose {#sec1}
=======

Soft tissue sarcomas (STSs) of the extremities are not commonly seen, and usually occurs in less than 1% of all adult tumors, but make up nearly half of all soft tissue sarcomas \[[@cit0001]\]. Many patients present with a progressively enlarging painless swelling \[[@cit0001], [@cit0002]\]. Symptoms like local pain, neuralgias, or restriction of motor function can result later due to the involvement of nerve bundles, bone, or significant muscular compartment \[[@cit0002]\]. Radiotherapy and surgery have been the standard modalities in the treatment of extremity soft tissue sarcomas. Tumor grade is considered one of the main prognostic factors. Low-grade tumors predominantly have the risk of local recurrence, requiring only adjuvant radiotherapy. On the other hand, most patients with intermediate or high-grade tumors larger than 5 cm in size, develop distant metastases compared to less than 10% in low-grade lesions or less than 5 cm in size \[[@cit0003], [@cit0004]\].

Adjuvant radiotherapy either used as interstitial brachytherapy or external beam radiotherapy (EBRT) has been found to improve local control rates (LC) in patients who have undergone limb-sparing resections with Level 1 evidence available \[[@cit0005], [@cit0006]\]. For completely resected high-grade sarcomas of the extremities, brachytherapy can be used as the sole therapy if the target volume is localized and accessible, as it gives high doses to the tumor bed and extremely low doses to tissues outside the treated volume \[[@cit0007]\]. Data also suggests improved outcome with a combination of brachytherapy (interstitial) and EBRT for patients with positive margins \[[@cit0008], [@cit0009], [@cit0010]\].

Clinical and treatment details {#sec2}
==============================

Case history ([Table 1](#t0001){ref-type="table"}) {#sec2.1}
--------------------------------------------------

### Case 1 {#s2a1}

A 48-year-old female patient was referred to the Radiotherapy Department for post-operative radiotherapy for a soft tissue sarcoma of the right shoulder. She presented with a history of a swelling developed over a six-month period (size and surgery details are not available), for which she subsequently underwent excision but no adjuvant therapy. A year later, the patient developed a 10 cm x 6 cm recurrence, at the same site for which she presented to our Institute. A biopsy was done and it reported a low-grade fibrosarcoma, and metastatic workup was negative. The patient was advised surgery followed by adjuvant radiotherapy or surgery, and intra-operative interstitial brachytherapy as either single radiation modality or with external beam therapy. However, because of extensive horizontal spread of tumor and the proximity of humeral head with fears of graft rejection of post-interstitial brachytherapy, the patient was planned for surgery and post-operative radiotherapy. The patient then underwent wide local excision of the tumor and the histopathological review reported dermatofibrosarcoma with an involvement of the deep resected margin. Patient has been treated by external beam photon irradiation with 6 MV photons, using AP-PA portals, with MLC blocking for lung shielding and use of bolus over surgical scar to a dose of 40 Gy in 20 fractions. After EBRT, a boost with surface mould brachytherapy using a base of thermoplastic immobilizer with wax mould was given ([Figures 1](#f0001){ref-type="fig"} and [2](#f0002){ref-type="fig"}). The patient received brachytherapy boost with dose of 3.5 Gy per fraction, twice daily, for seven fractions. Treatment was completed in February 2014.

###### 

Patient characteristics

  Total number of cases   Number
  ----------------------- --------
  Males                   1
  Females                 2
  Age group (years)       
   31-40                  1
   41-50                  2
   ≥ 51                   0
  Site involved           
   Site involved          0
   Chest wall             1
   Shoulder               2
  Type of lesion          
   Primary                2
   Recurrent              1

![Upper torso mould used in the first patient with extensive involvement of right shoulder tissue](JCB-9-29867-g001){#f0001}

![**A)** Site of mould in the first patient. **B)** Computed tomography image with mould in place in the first patient](JCB-9-29867-g002){#f0002}

### Case 2 {#s2a2}

A 45-year-old female patient was referred to the Radiotherapy Department for post-operative radiotherapy for soft tissue sarcoma of left chest wall. She presented with a swelling over the left upper part of the chest in the infra-clavicular region developing over three years, and was operated at another hospital in January 2014 (size and surgery details are not available). A post-surgery histopathological review reported dermatofibrosarcoma protuberans with deep resected margin involved by tumor. The patient was subsequently treated by external beam photon irradiation with 6 MV photons, using conventional AP-PA portals with lung shielding and use of bolus (of 0.5 cm thickness) over the surgical scar to a prescribed dose of 40 Gy in 20 fractions. This was followed by a boost, with surface mould brachytherapy to a dose of 3.5 Gy per fraction, twice daily for 7 fractions ([Figure 3](#f0003){ref-type="fig"}). The patient completed treatment in April 2014.

![**A)** Dose color wash and **B)** 3D dose reconstruction of treated area in the second patient](JCB-9-29867-g003){#f0003}

### Case 3 {#s2a3}

A 36-year-old male patient has been referred to the Radiotherapy Department for post-operative radiotherapy of soft tissue sarcoma of the anterior shoulder at left side. He had presented in another hospital with a swelling of the left anterior shoulder over ten months. Local examination reported an 8 x 6 cm mass lesion with no nodes or restriction of mobility. The patient underwent surgery. The post-surgery histopathological review reported the mass as a low-grade sarcoma with fibro sarcomatous pattern and with involved deep margin. The patient then received external beam radiotherapy with 6 MV, using AP-PA portals with the use of bolus of 0.5 cm over surgical scar to a dose of 44 Gy in 22 fractions, followed by a boost with surface mould brachytherapy to a dose of 3.5 Gy per fraction twice daily for six fractions. The patient completed treatment in June 2014.

Mould preparation {#sec2.2}
-----------------

Each mould was prepared from a framework of thermoplastic sheet molded to the patient's anatomy, and then covered by thin layer of dental wax. After marking of target volume by the oncologist, the physicist helped to make an initial cut-out with thermoplastic sheet. Then the wax was heated in a water heater, and cast in the required shape over the thermoplastic and molded according to local anatomy. The shaped wax mould was approximated to the lesion in the treatment position, matched with lesion surface and local anatomy, edges were trimmed and smoothened. Catheters were fixed to the mould, which was then placed on the patient to check the feasibility of placement and target volume coverage ([Figure 1](#f0001){ref-type="fig"}). The lesion was then marked with lead wires and computed tomography (CT)-simulation of the patient in the treatment position was done with mould in place.

Treatment planning and delivery {#sec2.3}
-------------------------------

After CT-simulation, image reconstruction, target volume contouring, and treatment planning was carried out on Eclipse (Varian Medical Systems, Palo Alto, CA, USA) TPS version 10.0, and treatment delivery was done on GammaMedplusiX (Varian Medical Systems, Palo Alto, CA, USA). The target volume was defined as the volume encompassing the tumor bed with lateral margins of 2-2.5 cm and depth of 1-1.5 cm. The tumor bed has been identified by comparing pre-operative and post-operative CT/magnetic resonance (MR) films, as well as taking into account the surgical scar. Dosimetry has been done using volume optimization techniques. The dose was prescribed to 80%, 85%, and 90% isodose lines, respectively, in the three cases in order to cover the depth of 1-1.5 cm ([Figures 2](#f0002){ref-type="fig"}, [3](#f0003){ref-type="fig"} and [4](#f0004){ref-type="fig"}). Treatments were delivered twice daily, six hours interval, and review of reactions was done every third day and at the completion. Evaluation was done of planning details, response to therapy, and reactions encountered.

![**A)** Dose color wash in the second patient. **B)** Isodose distribution with overlying catheters in the third patient](JCB-9-29867-g004){#f0004}

Observations {#sec2.4}
------------

All patients tolerated the mould boost well with skin darkening as observed towards the end of treatment, and grade 2 skin changes seen in the second and third patients. Grade 1 skin changes were seen in all three cases ([Figure 5](#f0005){ref-type="fig"}). Brachytherapy dose ranged from 21-24.5 Gy in fraction sizes of 3.5 Gy, delivered twice daily. Brachytherapy part EQD~2~ of these patients were 24 and 28.6 Gy, while total EQD~2~ of these patients was 68.5 Gy in the three cases. Biologically equivalent dose for 3 and 10 Gy has been also calculated ([Table 2](#t0002){ref-type="table"} and [Figure 6](#f0006){ref-type="fig"}) in all cases, and the total BED~3~ dose (including external beam component) has been between 119-129 Gy in all cases. Selecting an isodose of 85-100% ([Figure 7](#f0007){ref-type="fig"}) helped in achieving maximal tumor volume coverage, while at the same time, keeping volume of tissue receiving more than 150% (V~150~) to below 2% and volume of tissue receiving more than 200% (V~200~) of prescribed dose to below 0.001%. This meant that areas receiving more than 200% of the prescribed dose were limited to the substance of the mould ([Table 3](#t0003){ref-type="table"} and [Figure 7](#f0007){ref-type="fig"}). The underlying bone in all cases was the organ at risk (OAR). Maximum dose to OAR was assessed as dose to 2 cc of OAR and ranged between 55-87% of the prescribed dose with a median dose being 80% ([Figure 8](#f0008){ref-type="fig"}).

###### 

Dose characteristics

  Age/sex   Brachytherapy dose   EBRT dose   No. of channels   EQD~2~ cGy   Brachytherapy dose                                
  --------- -------------------- ----------- ----------------- ------------ -------------------- -------------------- ------- -------
  48/F      24.5 (3.5)           7           40 Gy             20           28                   40 + 28.58 = 68.58   53.17   33.08
  45/F      24.5 (3.5)           7           40 Gy             20           4                    40 + 28.58 = 68.58   53.17   33.08
  36/M      21.0 (3.5)           6           44 Gy             22           8                    44 + 24.50 = 68.50   56.07   28.35

EQD~2~ -- equivalent dose at 2 Gy per fraction, BED~3Gy~/BED~10Gy~ -- biologically equivalent dose for late effects (BED~3Gy~) and for early effects (BED~10Gy~)

-- fraction, EBRT -- external beam radiation therapy

###### 

Dose volume comparisons

  Case number   Age/sex   Prescription isodose to PTV   V~200%~   V~150%~   Depth of PTV coverage   Lateral margins for PTV   \% PTV covered by prescription isodose
  ------------- --------- ----------------------------- --------- --------- ----------------------- ------------------------- ----------------------------------------
  1             48/F      80%                           0.001%    1.0%      1.1                     2.0 cm                    100
  2             45/F      85%                           0.001%    0.5%      1.2                     2.5 cm                    80
  3             36/M      90%                           0.001%    0.6%      1.6                     2.0 cm                    70

PTV -- planning target volume, V~200%~ -- volume receiving 200% of prescribed dose, V~150%~ -- volume receiving 150% of prescribed dose

![Immediate post-radiotherapy skin changes in the third patient](JCB-9-29867-g005){#f0005}

![Biologically equivalent dose (BED) of treated cases](JCB-9-29867-g006){#f0006}

![Tissue volume and dose received](JCB-9-29867-g007){#f0007}

![Dose to organ at risk (head of humerus)](JCB-9-29867-g008){#f0008}

Sequelae and survival {#sec2.5}
---------------------

There were no severe skin reactions like ulcers or necrosis ([Table 4](#t0004){ref-type="table"}). At six months of follow-up, none of the patients showed any local or distal recurrence both clinically as well by imaging (CT thorax and local MRI). All the cases again reported for follow-up in March 2015, in August 2015, in January 2016, July 2016, October 2016, and January 2017 ([Figures 9](#f0009){ref-type="fig"} and [10](#f0010){ref-type="fig"}). By then, patients had completed 36, 34, and 32 months uneventful follow-up, respectively. Local examination and imaging showed no local recurrence or distant metastases or even no local site late treatment sequelae ([Figure 11](#f0011){ref-type="fig"}, [Table 4](#t0004){ref-type="table"}).

###### 

Skin reactions and survival

  Case number   Skin reactions grade at 4 weeks post-brachytherapy (acute reactions)   Skin reactions/scar/fibrosis at 30 months post-brachytherapy (late effects)   Follow-up period (in months)   Disease free survival (in months)                            
  ------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------ ----------------------------------- ---- ---- ---- ---- ---- ----
  1             Yes                                                                    No                                                                            No                             No                                  No   No   No   No   36   36
  2             Yes                                                                    Yes                                                                           No                             No                                  No   No   No   No   34   34
  3             Yes                                                                    Yes                                                                           No                             No                                  No   No   No   No   32   32

![Skin changes in the first patient, photograph taken 3 months post-radiotherapy](JCB-9-29867-g009){#f0009}

![Magnetic resonance imaging in the third patient, photograph taken at 27 months post-radiotherapy showing no local recurrence](JCB-9-29867-g010){#f0010}

![Disease free survival (DFS) of treated cases](JCB-9-29867-g011){#f0011}

Discussion {#sec3}
==========

Post-operative or adjuvant radiotherapy in soft tissue sarcomas are indicated in situations with increased risk of local recurrence after surgery. These include cases with narrow or positive surgical margins, local recurrence after prior surgery, tumor size of more than 5 cm, as well as lesions deep to or invading the superficial fascia, high grade, or age of patient younger than 50 years \[[@cit0003]\].

Interstitial brachytherapy has been more commonly used and can achieve good dose distribution especially in limited target volumes, and helps to achieve good control rates \[[@cit0011], [@cit0012]\]. Early results from Memorial Sloan-Kettering Cancer Center (MSKCC) have shown better results when the brachytherapy is added to radiotherapy as adjuvant therapy, especially in cases with positive margins \[[@cit0008]\] as well as in recurrent disease \[[@cit0009], [@cit0013]\]. In France, the Gustav Roussy Institute reported 80% local control rates with interstitial brachytherapy, but 30% margin failures and a 35% necrosis rate \[[@cit0014]\]. However, the use of interstitial brachytherapy in the treatment of sarcomas is associated with certain constraints. These include difficulty in covering a larger target volume, limits in catheter patterns, achieving good geometry because of the presence of bone or visceral organs or difficult anatomic sites such as around the shoulder, and risk of radiation injury to nerves that are in direct contact with the BT catheters. The MSKCC group noticed that shoulder location was an independent prognostic factor for poor local control with interstitial brachytherapy \[[@cit0007]\]. Therefore, in many of these situations, particularly when the target volume is superficially located, a customized mould using acrylic or thermoplastic casts can be used for catheter placement, geometry, and even the immobilization. The brachytherapy catheters are laid directly onto the mould or can be used with a spacer such as in Freiburg flap to ensure uniform catheter distribution.

Compared to interstitial brachytherapy, surface mould brachytherapy though extensively studied in skin cancers, head and neck, scalp, or even intra-ocular regions, has not been widely used for treating extremity soft tissue sarcomas, and dose guidelines have to be extrapolated from interstitial brachytherapy. These custom-made external molds can result in dose distribution with a sharp gradient in the edges of the applicator, especially over curved or irregular surfaces, and are easy to use with highly accurate daily treatment reproduction. They enable one to obtain excellent local control with minimum treatment-related sequelae or late complications. In our case series, the position of the tumor bed in all the three cases was very close to the head of humerus and with deep involved margins, and the need was not only to adequate cover the area at risk, but also to achieve sharp dose fall-off to avoid the joint or bone. It is better to prescribe to isodose of 85-100% to obtain an acceptable coverage of the target volume to limit the amount of tissue irradiated by 150% isodose. Any attempt to pull the isodose outward to cover a bigger target volume altogether could result in more tissue receiving doses above 200% and cause severe skin reactions. In all our cases, the authors managed to keep the area receiving dose of 200% and above to within the substance of the mould, while area receiving above 150% is less than 2%. Thus, the use of surface moulds can result in dose distributions more homogeneous than even electron beam therapy \[[@cit0015]\], and may even rival IMRT with the added benefits of minimal surrounding tissue dose and much less integral body dose \[[@cit0016]\]. In our series, we noticed grade 1 skin changes in all cases and grade 2 reactions in 2 cases. Furthermore, all reactions healed within six weeks.

Conclusions and learning points {#sec4}
===============================

Treatment of soft tissue sarcomas of the extremities requires usually combined modality therapy. Brachytherapy, usually interstitial, plays an useful role in the treatment of soft tissue sarcomas of the extremities helping achieve improved local control with both organ and function preservation.

Surface mould brachytherapy can be a valuable alternative to interstitial brachytherapy, especially in cases where the target volume is extensively superficial, underlying critical structures, and where catheter placement may be difficult, such as the shoulder, with excellent medium term local control and mild toxicity.
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